Table 3.

CSCs-specific nucleic acid drugs and their implications.

Sr. no.	Source and marker of CSC	Therapeutic agent and drug delivery system	Mechanism of CSC depletion	References
1.	HNSCC, patient-derived cells, ALDH1+/CD44+	siEZH2/siOct4	Repression of EMT program	Lo et al., 2010
		PU-PEI
2.	Gastric cancer, BGC823 cells, CD44+	microRNA-200c	Regulation of self-renewal, invasiveness and differentiation	Cui et al., 2014
		Gelatinase-stimuli PEG-Pep-PCL nanoparticle
3.	Melanoma, B16F10 cells, CD44+	microRNA-34a	Regulation of CSC differentiation and metastasis	Shi et al., 2013
		Solid lipid nanoparticles (SLNs)
4.	Non-small cell lung cancer, H1650 cells, side population	shAnxA2	Inhibition of resistant phenotype of SP cells	Andey et al., 2014
		Liposomal (cationic ligand-guided, CLG)
5.	Glioblastomas, U87MG and U251 cells, CD133+	siGLUT3	Metabolism of glioma SC targeting	Xu et al., 2015
		Cationic lipid-assisted PEG-b-PLA nanoparticle
6.	Colon cancer, CHOK1 cells, CD133+	siMDR1	Silencing of multidrug resistance gene	Liu et al., 2009
		Nanoparticle consisting of PEI(1200), polyethylene glycol and lipid-based cross linking moiety
7.	HNSCC, CAL27 cell, etc., Nanog, Oct3/4, and Sox2	Pre-miR-107	miR-107 mediated suppression of tumor growth	Piao et al., 2012
		Cationic lipid nanoparticles
8.	Acute myeloid leukemia, KG-1 and KG-1a cells, CD34+	siCD44	Inhibition of LSC interactions with microenvironment	Gul-Uludag et al., 2014
		Nanoparticle consisting of PEI2-caprylic acid and PEI2-linoleic acid
9.	Glioblastomas, patient-derived cells, CD133+; lung cancer, patient-derived cells, CD133+	microRNA-145	Regulation of stem cell-like genes; Inhibition of the EMT program and metastatic ability.	Chiou et al., 2012; Yang et al., 2012
		Polyurethane-short branch polyethyleneimine (PU-PEI) as delivery vehicle